Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma

Eun Jin Yoo, Hye Sun Shin, Seung Up Kim, Dong Jin Joo, Jun Yong Park, Gi Hong Choi, Do Young Kim, Sang Hoon Ahn, Jinsil Seong, Myung Joo Koh, Kwang Hyub Han, Chae Yoon Chon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We herein report a patient with advanced hepatitis B virus-related hepatocellular carcinoma (HCC) beyond the Milan criteria. He underwent orthotopic liver transplantation after successful HCC downstaging that satisfied the University of California, San Francisco criteria, using concurrent chemoradiation therapy with a combination of repeated hepatic arterial infusion chemotherapy (HAIC) and sorafenib. A 52-year-old male was diagnosed with advanced hepatitis B virus-related HCC beyond the Milan criteria. He underwent concurrent chemoradiation therapy (50 Gy with 20 fractions over 5 weeks with HAIC using 5-fluorouracil at a dose of 500mg/day, which was administered during the first and fifth weeks of radiation therapy) as an initial treatment modality. This was followed by the combined use of HAIC using 5-fluorouracil (500mg/m2 for 5hours on days 1-3) and cisplatin (60mg/m2 for 2hours on day 2) every 4 weeks (twelve cycles) and sorafenib (from the third to the twelfth cycle of HAIC) to treat the remaining HCC. Because a remarkable decrease in the tumor burden that satisfied the University of California, San Francisco criteria was observed after these combination treatments, the patient underwent orthotopic liver transplantation with curative aim and survived for 11 months without evidence of HCC recurrence.

Original languageEnglish
Pages (from-to)755-759
Number of pages5
JournalOncoTargets and Therapy
Volume6
DOIs
Publication statusPublished - 2013 Jul 15

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Drug Therapy
San Francisco
Liver
Hepatitis B virus
Fluorouracil
Therapeutics
Tumor Burden
Cisplatin
Radiotherapy
sorafenib
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{2d9835f2a8cb4cc999bd1b9fbddfcad1,
title = "Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma",
abstract = "We herein report a patient with advanced hepatitis B virus-related hepatocellular carcinoma (HCC) beyond the Milan criteria. He underwent orthotopic liver transplantation after successful HCC downstaging that satisfied the University of California, San Francisco criteria, using concurrent chemoradiation therapy with a combination of repeated hepatic arterial infusion chemotherapy (HAIC) and sorafenib. A 52-year-old male was diagnosed with advanced hepatitis B virus-related HCC beyond the Milan criteria. He underwent concurrent chemoradiation therapy (50 Gy with 20 fractions over 5 weeks with HAIC using 5-fluorouracil at a dose of 500mg/day, which was administered during the first and fifth weeks of radiation therapy) as an initial treatment modality. This was followed by the combined use of HAIC using 5-fluorouracil (500mg/m2 for 5hours on days 1-3) and cisplatin (60mg/m2 for 2hours on day 2) every 4 weeks (twelve cycles) and sorafenib (from the third to the twelfth cycle of HAIC) to treat the remaining HCC. Because a remarkable decrease in the tumor burden that satisfied the University of California, San Francisco criteria was observed after these combination treatments, the patient underwent orthotopic liver transplantation with curative aim and survived for 11 months without evidence of HCC recurrence.",
author = "Yoo, {Eun Jin} and Shin, {Hye Sun} and Kim, {Seung Up} and Joo, {Dong Jin} and Park, {Jun Yong} and Choi, {Gi Hong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Jinsil Seong and Koh, {Myung Joo} and Han, {Kwang Hyub} and Chon, {Chae Yoon}",
year = "2013",
month = "7",
day = "15",
doi = "10.2147/OTT.S45602",
language = "English",
volume = "6",
pages = "755--759",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. / Yoo, Eun Jin; Shin, Hye Sun; Kim, Seung Up; Joo, Dong Jin; Park, Jun Yong; Choi, Gi Hong; Kim, Do Young; Ahn, Sang Hoon; Seong, Jinsil; Koh, Myung Joo; Han, Kwang Hyub; Chon, Chae Yoon.

In: OncoTargets and Therapy, Vol. 6, 15.07.2013, p. 755-759.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma

AU - Yoo, Eun Jin

AU - Shin, Hye Sun

AU - Kim, Seung Up

AU - Joo, Dong Jin

AU - Park, Jun Yong

AU - Choi, Gi Hong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Seong, Jinsil

AU - Koh, Myung Joo

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

PY - 2013/7/15

Y1 - 2013/7/15

N2 - We herein report a patient with advanced hepatitis B virus-related hepatocellular carcinoma (HCC) beyond the Milan criteria. He underwent orthotopic liver transplantation after successful HCC downstaging that satisfied the University of California, San Francisco criteria, using concurrent chemoradiation therapy with a combination of repeated hepatic arterial infusion chemotherapy (HAIC) and sorafenib. A 52-year-old male was diagnosed with advanced hepatitis B virus-related HCC beyond the Milan criteria. He underwent concurrent chemoradiation therapy (50 Gy with 20 fractions over 5 weeks with HAIC using 5-fluorouracil at a dose of 500mg/day, which was administered during the first and fifth weeks of radiation therapy) as an initial treatment modality. This was followed by the combined use of HAIC using 5-fluorouracil (500mg/m2 for 5hours on days 1-3) and cisplatin (60mg/m2 for 2hours on day 2) every 4 weeks (twelve cycles) and sorafenib (from the third to the twelfth cycle of HAIC) to treat the remaining HCC. Because a remarkable decrease in the tumor burden that satisfied the University of California, San Francisco criteria was observed after these combination treatments, the patient underwent orthotopic liver transplantation with curative aim and survived for 11 months without evidence of HCC recurrence.

AB - We herein report a patient with advanced hepatitis B virus-related hepatocellular carcinoma (HCC) beyond the Milan criteria. He underwent orthotopic liver transplantation after successful HCC downstaging that satisfied the University of California, San Francisco criteria, using concurrent chemoradiation therapy with a combination of repeated hepatic arterial infusion chemotherapy (HAIC) and sorafenib. A 52-year-old male was diagnosed with advanced hepatitis B virus-related HCC beyond the Milan criteria. He underwent concurrent chemoradiation therapy (50 Gy with 20 fractions over 5 weeks with HAIC using 5-fluorouracil at a dose of 500mg/day, which was administered during the first and fifth weeks of radiation therapy) as an initial treatment modality. This was followed by the combined use of HAIC using 5-fluorouracil (500mg/m2 for 5hours on days 1-3) and cisplatin (60mg/m2 for 2hours on day 2) every 4 weeks (twelve cycles) and sorafenib (from the third to the twelfth cycle of HAIC) to treat the remaining HCC. Because a remarkable decrease in the tumor burden that satisfied the University of California, San Francisco criteria was observed after these combination treatments, the patient underwent orthotopic liver transplantation with curative aim and survived for 11 months without evidence of HCC recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84879814946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879814946&partnerID=8YFLogxK

U2 - 10.2147/OTT.S45602

DO - 10.2147/OTT.S45602

M3 - Article

C2 - 23836988

AN - SCOPUS:84879814946

VL - 6

SP - 755

EP - 759

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -